Minoxidil

Generic Name: Minoxidil

Brand Names: Loniten, Minox, Regoxidine, Rogaine

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₅N_₅O

CAS Number: 38304-91-5

Unique Ingredient Identifier: 5965120SH1

Background: A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure.

Indication: For the treatment of severe hypertension and in the topical treatment (regrowth) of androgenic alopecia in males and females and stabilisation of hair loss in patients with androgenic alopecia.

Associated Conditions: Androgenetic Alopecia (AGA), Severe, symptomatic Hypertension

Clinical Trials

Minoxidil 1% for Eyebrow Enhancement

Phase 4

Completed

Conditions: Eyebrow Hypotrichosis
Thin Eyebrow

Interventions: Drug: Minoxidil lotion 1%
Drug: Placebo

First Posted Date: 2013-08-16

Last Posted Date: 2014-04-22

Lead Sponsor: Mae Fah Luang University Hospital

Target Recruit Count: 40

Registration Number: NCT01924000

Locations: 🇹🇭
Mae Fah Luang University Hospital (Bangkok), Bangkok, Thailand

A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss

Phase 2

Completed

Conditions: Female Pattern Hair Loss
Androgenetic Alopecia (AGA)
Ludwig Type 1
Ludwig Type 2

Interventions: Drug: Pantovigar
Drug: Minoxidil 2% only

First Posted Date: 2013-07-16

Last Posted Date: 2013-12-12

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 74

Registration Number: NCT01900041

Locations: 🇷🇺
Moscow Scientific Clinical Center of Dermatology and Cosmetology, Moscow, Russian Federation
🇷🇺
State Scientific Center of Dermatology and Cosmetology, Moscow, Russian Federation

Minoxidil 2% for Eyebrow Enhancement

Phase 4

Completed

Conditions: Hypotrichosis of Eyebrows
Thinning Eyebrows

Interventions: Drug: Minoxidil lotion 2%
Drug: Placebo

First Posted Date: 2012-08-24

Last Posted Date: 2013-06-19

Lead Sponsor: Mae Fah Luang University Hospital

Target Recruit Count: 40

Registration Number: NCT01672307

Locations: 🇹🇭
MFL University Hospital (Bangkok), Bangkok, Thailand

Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients

Phase 3

Conditions: Female Pattern Alopecia

Interventions: Drug: Saline
Drug: Minoxidil

First Posted Date: 2012-08-01

Last Posted Date: 2013-09-25

Lead Sponsor: Brasilia University Hospital

Target Recruit Count: 60

Registration Number: NCT01655108

Locations: 🇧🇷
University of Brasilia, Brasilia, Distrito Federal, Brazil

Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia

Phase 1

Conditions: Objective (Goal)
Self-Assessment
Adverse Effects

Interventions: Drug: 5% Minoxidil solution
Drug: 5% MInoxidil milky lotion

First Posted Date: 2012-07-26

Last Posted Date: 2012-07-26

Lead Sponsor: Siriraj Hospital

Target Recruit Count: 20

Registration Number: NCT01650272

Locations: 🇹🇭
Siriraj Hospital, Bangkok, Thailand

Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss

Phase 3

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: 3%Minoxidil lotion
Drug: 3% Minoxidil with 0.1% Finasteride lotion

First Posted Date: 2011-07-11

Last Posted Date: 2012-07-20

Lead Sponsor: Mae Fah Luang University Hospital

Target Recruit Count: 40

Registration Number: NCT01391156

Locations: 🇹🇭
Mae Fah Luang University Hospital(Bangkok), Bangkok, Thailand

Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss

Phase 2

Completed

Conditions: Baldness
Alopecia

Interventions: Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C
Drug: bimatoprost vehicle solution
Drug: minoxidil 2% solution
Drug: bimatoprost Formulation A

First Posted Date: 2011-03-29

Last Posted Date: 2014-04-09

Lead Sponsor: Allergan

Target Recruit Count: 306

Registration Number: NCT01325350

Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

Phase 2

Completed

Conditions: Alopecia
Baldness
Alopecia, Androgenetic

Interventions: Drug: bimatoprost Formulation A
Drug: bimatoprost vehicle solution
Drug: minoxidil 5% solution
Drug: bimatoprost Formulation B
Drug: bimatoprost Formulation C

First Posted Date: 2011-03-29

Last Posted Date: 2014-04-10

Lead Sponsor: Allergan

Target Recruit Count: 307

Registration Number: NCT01325337

Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia

Phase 2

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: Minoxidil
Drug: vehicle of 5% Minoxidil topical foam

First Posted Date: 2011-03-21

Last Posted Date: 2013-11-07

Lead Sponsor: Natalie GARCIA BARTELS

Target Recruit Count: 70

Registration Number: NCT01319370

Locations: 🇩🇪
Charité-Universitätsmedizin Berlin, Clinical Research Center for Hair and Skin Science, Dept. of Dermatology, Venereology and Allergy, Berlin, Germany

Clinical Trial in Females for Female Pattern Hair Loss

Phase 3

Completed

Conditions: Androgenetic Alopecia

Interventions: Drug: 5% Minoxidil Topical Foam
Drug: Vehicle Topical Foam

First Posted Date: 2010-10-22

Last Posted Date: 2014-06-10

Lead Sponsor: Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.

Target Recruit Count: 404

Registration Number: NCT01226459

Locations: 🇺🇸
Axis Clinical Trials, Los Angeles, California, United States
🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸
Derm Research Center of New York, Stony Brook, New York, United States

and more 13 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy